Sunday, October 19, 2014

Science literacy and Ebola Virus: This is a letter submitted to my local newspapers


If there was a safe vaccine against Ebola virus would you take it? I think most people would say yes. Yet why do so many Americans refuse flu vaccination, when thousands of American lives would be saved every year by flu vaccination? I find this contrast noteworthy.

 

Another interesting revelation for me during this Ebola virus scare is the high level of scientific illiteracy in this country.  People are faulting public officials for not knowing every detail about Ebola virus disease, not realizing that the scientific method is based on developing theories after gathering evidence.  Lack of scientific information can only be corrected by experimentation, which takes time, money, commitment at high levels and ethical practices (there are guidelines for experimentation in humans).  Theories may change, based on new evidence.  I believe that the level of irrational panic would be greatly reduced if Americans placed much higher value on science education and literacy.

Monday, October 13, 2014

My idea which may help stop the international spread of Ebola virus

REMEMBER YOU HEARD IT HERE FIRST!

1.       I have an idea that may help stop the international spread of Ebola virus.  Currently, Ebola virus disease is diagnosed first clinically (by symptoms), namely fever, headache, pain, vomiting and more.  Then it is diagnosed in laboratory testing for the actual virus chemical.  However, there is a gap in time between the moment of human exposure to the virus and the appearance of symptoms.  This is the notorious 2-21 day incubation period.  During that time the person is not infectious, ie, they do not transmit virus, but it is in their body.  The reason for the time lag is that the virus grows from probably a tiny inoculum to high enough levels of virus to cause disease. Think about if someone sneezes on you, you don’t get symptoms right away: it takes a few days before you feel sick.

 

2.       During those incubation days, when the virus is reproducing, there is an unseen battle between the virus and your immune system taking place.  You are not aware of the battle.  Then, if your immune system wins, you never even know it happened.  If the virus wins, and your immune system fails, you feel symptoms.  For most infectious diseases, there is no test for the incubation period.   We are now in an international crisis, so taking temperatures at departure and arrivals is important, but as has been seen, it will not prevent importing virus during the incubation period.

 

3.       I suggest INDIRECT testing for virus growth BEFORE symptoms appear.  At the moment is it technically too challenging to find and detect the low and dispersed amounts of virus.   However, during the aforementioned battle between the virus and the immune system, there are changes in the body and the immune system that may be detectable before symptoms appear.  Something called “Type 1 Interferons” are among the first proteins induced as part of the innate immune response in the beginning of a virus infection.  These proteins are well-known and well-studied and human diagnostic kits are commercially available.  Just like any other detective work, we should be able to find clues; remnants of battles that may be helpful in the current crisis.

 

4.       There are many other proteins, called pro-inflammatory cytokines, chemokines, pattern recognition receptors and others that change in the early stages of a clinical infection. There are published scientific reports about human proteins that change, either increase or decrease in abundance in the human body during Ebola virus infection, possibly early in the process, possibly even before symptoms appear. 

 

5.       Many of these tests are already commercially available. For example: C-reactive protein (CRP) is used as a flag indicating the body’s response to acute and chronic inflammation, myocardial infarction, bacterial infections and other events.   A blood test for gamma interferon is used to predict development of active from latent tuberculosis.

 

6.       I suggest making these tests available on an investigative, situational, off-label and provisional basis. Such a test could be part of a panel of tests, which now includes country of origin and temperature before entry or departure at international airports. Even if the tests are not FDA approved for CLINICAL human treatment, it might be useful as a preliminary airport screening.  Before objections are raised about cost and practicality, this is a simple idea and if it works, would go far towards mitigating the unbridled, unsubstantiated frenzy surrounding an already difficult situation.  It is probably relatively inexpensive, considering the costs that are either current or anticipated.

Here is a (certainly incomplete) list of company selling these products.  These are simply from web searches, I have no interest in any of these companies or their products.

COMPANY
PRODUCT
C-reactive protein (CRP)
 
Predict development of active tuberculosis from latent tb.
 
pattern recognition receptors
Nyumerous kets for testing innate immunity
 
 

 

3.

Expert Rev Clin Immunol. 2014 Jun;10(6):781-90. doi: 10.1586/1744666X.2014.908705. Epub 2014 Apr 18.




  • 1Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street Winnipeg, MB, R3E 3R2 Canada.

Abstract

Ebola causes highly lethal hemorrhagic fever in humans with no licensed countermeasures. Its virulence can be attributed to several immunoevasion mechanisms: an early inhibition of innate immunity started by the downregulation of type I interferon, epitope masking and subversion of the adaptive humoural immunity by secreting a truncated form of the viral glycoprotein. Deficiencies in specific and non-specific antiviral responses result in unrestricted viral replication and dissemination in the host, causing death typically within 10 days after the appearance of symptoms. This review summarizes the host immune response to Ebola infection, and highlights the short- and long-term immune responses crucial for protection, which holds implications for the design of future vaccines and therapeutics.

Cell Host Microbe. 2013 Jul 17;14(1):5-6. doi: 10.1016/j.chom.2013.07.004.




  • 1Department of Biochemistry and State Key Laboratory for Liver Research, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong.

Abstract

The sensing of viral RNA by the host innate immune system is mediated by RIG-I and its partner PACT. In this issue of Cell Host & Microbe, Luthra et al. (2013) show that the Ebola virus VP35 protein counteracts the action of PACT at the cost of compromising its own function in viral replication.

Copyright © 2013 Elsevier Inc. All rights reserved.

Comment on


8.

J Interferon Cytokine Res. 2014 Feb;34(2):79-89. doi: 10.1089/jir.2013.0035. Epub 2013 Oct 8.




  • 11 Program in Genomics of Differentiation, National Institute of Child Health and Human Development , National Institutes of Health, Bethesda, Maryland.

Abstract

Ebola viruses (EBOV) can cause severe hemorrhagic disease with high case fatality rates. Currently, no vaccines or therapeutics are approved for use in humans. Ebola virus-like particles (eVLP) comprising of virus protein (VP40), glycoprotein, and nucleoprotein protect rodents and nonhuman primates from lethal EBOV infection, representing as a candidate vaccine for EBOV infection. Previous reports have shown that eVLP stimulate the expression of proinflammatory cytokines in dendritic cells (DCs) and macrophages (MΦs) in vitro. However, the molecular mechanisms and signaling pathways through which eVLP induce innate immune responses remain obscure. In this study, we show that eVLP stimulate not only the expression of proinflammatory cytokines but also the expression of type I interferons (IFNs) and IFN-stimulated genes (ISGs) in murine bone marrow-derived DCs (BMDCs) and MΦs. Our data indicate that eVLP trigger host responses through toll-like receptor (TLR) pathway utilizing 2 distinct adaptors, MyD88 and TRIF. More interestingly, eVLP activated the IFN signaling pathway by inducing a set of potent antiviral ISGs. Last, eVLP and synthetic adjuvants, Poly I:C and CpG DNA, cooperatively increased the expression of cytokines and ISGs. Further supporting this synergy, eVLP when administered together with Poly I:C conferred mice enhanced protection against EBOV infection. These results indicate that eVLP stimulate early innate immune responses through TLR and type I IFN signaling pathways to protect the host from EBOV infection.

PMID:

24102579

[PubMed - indexed for MEDLINE]

PMCID:

PMC3924795

[Available on 2015/2/1]


Icon for Mary Ann Liebert, Inc.

 

Sunday, August 11, 2013

Letter I wrote to the Advocate against celebrating the Louisiana carbon-based economy


Letter to the Advocate:

I am writing in response to a letter on July 9, 2013 from Mr. Michael J. Oliver, Chief Executive Officer of the Committee of 100, a pro-industry lobby.  The letter is entitled: “Louisiana on the cusp of a new era” and celebrates 3 major ways in which current industry is ushering a new era of prosperity to Louisiana.  I beg to differ.  Granted, there may be short term revenue boosts to Louisiana business.  And these industries will offer lower gas and oil prices to Louisianans. However, most of the industries mentioned are carbon-fuel based.   These include fracking natural gas from the Haynesville shale, deep sea drilling and the first offshore liquefied natural gas fueling facility in the United States.  Simple chemistry reveals that whether gasoline, natural gas or liquefied natural gas is burned, carbon dioxide is produced.  There is no such thing as “clean natural gas.” There is no longer any question that global warming from CO2 emissions is raising sea levels; other catastrophes, such as food shortages, loom.   We and our descendants will all pay in the long run for the continued wanton exploitation of carbon-based fuels.  When New Orleans real estate values start falling due to imminent, permanent flooding, the short term profits will be rued.  A better use of our limited resources would be to focus on renewable energy.

Letter I wrote about Dr. Oz to a local publication

Thank you for your timely postings of Jewish news, which I generally find thoughtful and useful.  However, you recently featured a story about Dr. Oz visiting Israel (below).   While I have no objection to stories about visiting Israel, I object to Dr. Oz.  He is basically a charlatan, disguised as a physician.  He has achieved fame and fortune.  He does this by dishing out advice.  His “advice” might charitably be described as “not his area of expertise” (heart surgery).  But actually much of his advice is quackery and pseudoscience.   He promotes alternative medicine, numerology, homeopathy, supplements, naturopathy and more. These are not only unproven, they are dangerous if unsuspecting people substitute them for real medical treatment.  Moreover, his success reflects the growing anti-intellectual trend in this country and the world.  Considering the high proportion of Nobel laureates among Jews and the high intellectual standards to which we aspire, in my opinion, covering such a person in your newsletter gives the appearance of condoning him and thereby demeans your publication.  I have posted some web sites that challenge his views.

 

The wonderful visit of Oz

August 08, 2013

By BEN SALES


Tuesday, June 21, 2011

Stop the creationist wingnuts

THE SHORT VERSION:
The Creationists are trying again. Louisiana Legislature HB 580 takes AWAY from BESE their purview over textbook selection and hands it to local school boards. Contact your legislators ASAP.
The effort to repeal “Louisiana Science Education Act” failed, but science advocates will continue their efforts.
THE LONGer VERSION:
The first thing you notice about Zach Kopplin is how normal he looks. But he is nothing like an ordinary recent high school graduate. He has accomplished more in a few months than many adults can claim to accomplish in a lifetime. Hyperbole, perhaps. But appropriate in this case. Zach has taken on the mission of battling the anti-science wingnuts in Louisiana. He spoke June 18 at NOSHA. In 2008 the “Louisiana Science Education Act” passed the Louisiana legislature http://www.evolutionnews.org/2011/05/scientists_issue_letter_suppor046881.html. Couched in language about “critical thinking skills,” the bill allows the teaching of religion, specifically creationism and pro-life stances, in the classroom. To my mind, this is directly prohibited in the constitution. Apparently, not just my mind. However, apparently opponents of the bill, such as Zach, feel that a legal challenge would be slower and more expensive than “simply” repealing the act.
Louisiana is the only state that has a law like this, although apparently Texas is close—they have abolished teaching standards.
Ironically, Mitch Landrieu has been actively touting the new University Medical Center. But if Louisiana science is killed, there will be no students or scientists to work there. Louisiana is a laughing stock over this. Conventions will be cancelled.
Zach was involved in the recent (May 2011) unsuccessful attempt to repeal the act. http://www.evolutionnews.org/2011/05/scientists_issue_letter_suppor046881.html . At the NOSHA meeting (I am paraphrasing, I am not a reporter) he said that although they failed this year, they will keep trying and will eventually succeed. He felt it would succeed faster than a legal challenge to the bill.
Now, HB 580 is before the legislature. Louisiana Legislature HB 580 takes AWAY from BESE their purview over textbook selection and hands it to local school boards. You’d think that a political body would not willingly yield power, but apparently the political appointees do not want to make waves.
On his own initiative, Zack contacted a Nobel Laureate, who then got other Nobel Laureates to sign on to their opposition.
GOOD GUYS:
James Gill is great on this subject:
http://karencarterpeterson.com/2011/06/01/gill-louisianas-science-education-act-lacking-in-science/
http://www.nola.com/opinions/index.ssf/2011/06/louisiana_legislature_deserves.html
Barbara Forrest.
Louisiana Coalition for Science

Wednesday, January 27, 2010

Improving American Science: Part 3: A solution--Proposal for "Minimal Basic Research Funding Level"

Improving American Science:

FUNDING BASED ON NEED:

Minimal Basic Research Funding (MBRF)

A SERIES

NOTE: This 3-part series is part of a larger work-in-progress, in which many proposals regarding improving American science are set forth

Part 1: The current situation

Part 2: The problem

Part 3: A solution

Proposal for "Minimal Basic Research Funding Level" By Marion Freistadt

Series abstract

In this series, I discuss some problems with the funding of biomedical research in America today and propose some solutions. After discussing the current situation in Part I of this series, I describe the problem in the second part of the series. The problem being addressed here may be summarized as low return on investment. Large amounts of money are spent on research, yet much money and human effort is wasted. Supplies and equipment are purchased on arbitrary budget cycles, rather than as needed. Moral is low among many qualified scientists and some leave research (49% in one survey [http://www.amazon.com/Leaving-Science-Occupational-Scientific-Careers/dp/0871546949]). After discussing the difficulties, I propose a novel solution, which I call Minimal Basic Research Funding. I propose that researchers establish a “self-help” fund from their own money. I present estimates suggesting that, with small annual donations, in 5 years, 100 awards may be distributed. The psychological benefit of this safety net may save the careers of many scientists. This proposal may be characterized as research funding based on research need, rather than the peer review.

Summary of Part 1

In Part 1 http://thinkoutsidetheicosahedron.blogspot.com/ (Dec. 27, 2009 post), I described the current situation with regard to career paths for American, academic biomedical basic researchers (AABBR). After about 10 years of graduate and post-graduate training, the researcher seeks to acquire grants, generally from NIH (http://www.nih.gov/ National Institutes of Health, the federal government) while holding an academic position. I described the grant application process. A primary difficulty is passing the “peer-review” process. Universities have a vested interested in researchers’ acquisition of grant funding because in addition to the face value of grants, high overheads are charged.

Summary of Part 2

In Part 2, I discuss 4 problems with the current situation: 1. Why should progress in science be linked to money grubbing? 2. Wasted time and money, 3. Wasted materials, 4. Discouragement of scientists. First, I argue that pursuit of science and pursue of funding are two distinct functions and should not be inextricably linked. Next, I delineate ways in which applying for grant funding waste time and money. For example, a new study estimates that the cost of preparing a rejected grant as $40,000 (http://www.informaworld.com/smpp/content~content=a909104450). Wasted material is a consequence of finite budget time periods. Discouragement is the human cost. Many researchers experience undue stress, professional dissatisfaction. This may lead to clinical depression and/or possibly suicide. I reference several blogs that document these difficulties.

Summary of Part 3

In Part 3, I propose the establishment of Minimal Basic Research Funding. Here I establish the concept, and propose several ways that this could come about. If a researcher meets an established standard of productivity, yet lacks success in fund raising, a minimal level of funding which I call “Minimal Basic Research Funding (MBRF)” should be available to that person to continue researching. My proposal differs from others in that I suggest that researchers themselves contribute small amounts toward this end, similar to an insurance plan. In this document, I address several details of the proposal such as the establishment of criteria for productivity. I next address quantitative details. I propose the establishment of a 501c3 organization for this purpose. Using just researcher-based donations, I propose that in 5 years, if 3000 people donate $300 per year, sufficient funds would be available for 100 awards. Other sources would enhance the fund.

Part 3: A solution: Minimal Basic Research Funding

The basic idea and how to achieve it.

I propose that if a researcher meets an established standard of productivity, yet lacks success in fund raising, a minimal level of funding which I call “Minimal Basic Research Funding (MBRF)” should be available to that person to continue researching. This funding would NOT be based on merit or peer-review.

My first purpose here is simply to state the principle: this funding should be available. Getting agreement about this principle is a first step. At the moment, since this idea is in its inception, there is no single, definitive way to envision that this may be achieved. Many new, good ideas start this way. However, the means should not be confused with the ends. One important goal of this document is to explicitly state the principle.

My second purpose here is to propose one possible mechanism for achieving this. I believe my proposal is unique. I propose that researchers themselves help pay for this, similar to a voluntary unemployment insurance policy. There certainly may be other ways to achieve MBRF.

(NOTE: I am not proposing to do away with peer-review. Peer-review is a best practice and much better than cronyism or favoritism. However, for the reasons outlined in Part 2 of this series, it needs improvement.)

In this document, then, I discuss the details of this proposal.

Issues discussed below are:

1. How to establish an acceptable standard of productivity?

2. What level of funding should be provided?

3. How many people would need or use MBRF?

4. Criteria other than productivity for use of the fund.

5. Where would this funding come from?

1. How to establish an acceptable standard of productivity?

As a starting point, I would suggest that submitted (or accepted) publications and submitted grant applications are evidence of productivity. Some type of “committee” (Board of Directors or reporting to them) would be established to set productivity criteria. This committee should be composed of BOTH funded and unfunded researchers. Committees may be local or national. These could be web-based committees. Clearly, criteria for productivity evolve.

2. What level of funding should be provided?

The level of funding would be set by Board of Directors and may change over time. Levels will also depend on the specific research area. MBRF should not be a substitute for long-term funding. Compared to regular funding, the awards should be very low. Here, as an example, I make a suggestion based on my field, at the time that I was in this situation. I believe that with $5000/year, productive research (carried out by the PI) could be continued until major awards are received. It is to be used only for supplies. No personnel costs would be provided.

The committee will also establish criteria to minimize abuse and maximize successful funding independence. Eligibility is obviated by any other funding. Also a "buddy" system to link veteran funded researchers with unfunded researchers may help.

3. How many people would need or use MBRF?

This is very difficult to answer, for many reasons. Just to get started, I make some wild estimates. I will give two polar extremes: an extremely high and a relatively low estimate.

A high estimate

In Part 1 of this series, I estimated that there are 25,000 unfunded US researchers seeking funding. However, this is probably not the number that will be eligible for MBRF. Several requirements (discussed below), such as that the person have no funding and that he or she is actively pursuing research as evidenced by submitted or accepted publications, may mitigate this number.

A low estimate

For another estimate of researchers eligible for MBRF, envision a single academic biomedical research department. Examining one department’s website (http://tulane.edu/sse/cmb/faculty.cfm#CP_JUMP_678514), out of 19 faculty, 3 have NIH funding (http://projectreporter.nih.gov/reporter.cfm) totaling roughly $2 million for FY 2009. Of those without NIH funding, 6 have published in the last 2 years (http://www.ncbi.nlm.nih.gov/sites/entrez). These are the “active” researchers. Lacking other data, I estimate that of these 6, half may have non-NIH funding (collaborations, other federal sources, such as NSF, other nonprofit funding agencies, or industrial sources). This leaves an estimated 3 researchers in this department requiring MBRF.

According the Department of Education (http://nces.ed.gov/programs/digest/d08/tables/dt08_230.asp), there are 270 public and not-for-profit institutions that are involved in research at either a “very high” or “high” or “Doctoral” level (including medical schools). (There are 131 AAMC accredited medical schools in the US [http://www.aamc.org/medicalschools.htm].) I estimate that each institution has an average of 4 biomedical research departments carrying out basic research (nonmedical schools probably have 1; medical schools may have 6). So, 4 times 270 equals 1080 relevant departments. 1080 departments times 3 eligible researchers per department equals 3,240 eligible researchers in the US.

So my estimates vary from 3,240 (times $5000 per year equals $16.2 million per year) to approximately 25,000 ($125 million/year) American researchers seeking MBRF.

4. Criteria other than productivity

In addition to meeting the established criterion of productivity, there are two other criteria to be eligible for an award. First, the person must have no current funding, not even as a collaborator. Second, the person must be actively seeking funding. The goal of this funding is to permit the person to continue researching until he or she establishes him- or herself as a self-supporting researcher.

5. Where would this funding come from?

I propose starting a 501c3 organization. The purpose of the organization would be to provide a mechanism to fund MBRF. Input funds would be placed in an endowment, which would generate interest. When the fund reaches a certain level, awards will be distributed from interest. Awards would be granted to institutions, to be used exclusively by the researcher for proposed research, in the same way that research funding is currently granted. The money in the fund should managed by professional, independent managers. Salaries for managers are not included in these estimates.

The numbers

Table I. Endowment amounts required to award specified number of annual awards. Calculated by the formula: A = Ae^.0725 - A , where A is Award amount. (http://mathforum.org/library/drmath/view/54632.html ).

Number of annual awards

Total amount awarded

Endowment required

1

$5,000

$66,489

10

$50,000

$664,894

50

$250,000

$3,324,468

100

$500,000

$6,648,936

500

$2,500,000

$33,244,681

1,000

$5,000,000

$66,489,362

3,000

$15,000,000

$199,468,085

Table I shows the endowment amounts required to distribute specified number of annual awards, assuming an interest rate of 7.25% (compounded continuously). Thus, in order to distribute one award, the fund would need an endowment of $66,489, while to award 1000 awards, $66,489,362 would be required.

I propose that researchers pay for this themselves, at least in part.

This would work like an insurance fund. Each researcher would contribute a small amount.

Table II shows two 5 year scenarios: 100 people donating $100/year and 1000 people donating $1000/year. In each case, cumulative funds with interest are shown.

Table II. Accumulated funds based on amounts and numbers of donations.

Interest compounded continuously, calculated by the formula : A= Pert, where P = Principal, r = interest rate, t = time in years and A amount after time t. (http://cs.selu.edu/~rbyrd/math/continuous/)

Added to Endowment that year

Cumulative donations

Cumulative with 7.25% interest

100 donors, each donating $100/year

Year 1

10,000

10,000

$10,752

Year 2

10,000

20,000

$23,121

Year 3

10,000

30,000

$37,289

Year 4

10,000

40,000

$53,457

Year 5

10,000

50,000

$71,846

1000 donors, each donating $1000/year

Year 1

1,000,000

1,000,000

$1,075,193

Year 2

1,000,000

2,000,000

$2,312,079

Year 3

1,000,000

3,000,000

$3,728,896

Year 4

1,000,000

4,000,000

$5,345,710

Year 5

1,000,000

5,000,000

$7,184,586

Combining the information from the two tables, at the lowest level, 100 people contributing $100/year, in 5 years one award would be generated (based on Table I, endowment amount needed per award). This is a 1 award per 100 donors award rate. At this level, in 15 years the endowment would be $445,027, permitting close to 7 awards (data not shown). If 1000 people donated $1000/year, after 1 year, $1,075,193 would permit close to 15 awards. After 5 years at this level, $7,184,586 would permit 108 awards.

To fund 3000 researchers, $200 million would be needed. This could be reached in 10 years if 5000 people gave $2000/year.

This level of funding for a nonprofit, charitable organization is not extravagant. Endowments of the wealthiest 25 charitable foundations on March 4, 2008 (http://en.wikipedia.org/wiki/List_of_wealthiest_foundations ) range from $3.3 billion (Kresge) to $35.1 billion (Bill and Melinda Gates). In fact, compared to the overall annual NIH budget ($30 billion), $200 million is 0.7%. Considering that this could be saving or improving the careers of thousands of scientists, this is not expensive.

Obviously, getting 5000 people to donate $2000 per year for 10 years would be difficult. Other revenue sources would be required. However, I believe that this general approach, at a lower level, is feasible in the short term.

For the researcher-supported part of the fund, I propose an intermediate-sized, medium range target: 3000 people donate $300 per year ($25/month). This would achieve $6,466,127 in 5 years, permitting 100 awards.

Incentives for researchers to contribute:

1. It’s cheap. Researchers for whom this is relevant are presumably already employed, so they can usually afford a small amount such as $25-$100/month.

2. It would be 100% tax-deductible, so donations could automatically be deducted from payroll and included in the cafeteria plan.

3. A researcher must contribute to receive an award.

Several additional points must be made here. First, this is NOT a personal investment. Money donated is not returned and there is no “return on investment.” Like a church or synagogue, it is not a “fee for service.” You cannot only contribute when it’s time for your child’s bar mitzvah: the organization needs to run all the time. It is like insurance, in the sense that you hope you never have to make a claim. If the fund disbands completely, money should be returned to donors, with interest (less expenses).

Who will donate?

I believe that any researcher who has gone through the process of desperately needing grant awards and having all applications rejected, will be sympathetic to this cause. Given overall success rates of 25% and first time success rates of 10%, this is a significant proportion of the biomedical science population. Ultimately, most scientists may wish to donate, since they realize that they someday may face the same situation.

Other possible revenue sources

In the long term, other sources of revenue will be required. These may come from existing research funding mechanisms or from new fund-raising options.

NIH or other relevant federal agencies

The simplest solution would be if NIH or research institutions provided this funding. It has been shown (in Canada) that the cost of submitting rejected grant applications exceeds the cost of small grants themselves. (“Cost of the NSERC Science Grant Peer Review System Exceeds the Cost of Giving Every Qualified Researcher a Baseline Grant”

http://www.informaworld.com/smpp/content~content=a909104450

http://scienceblogs.com/clock/2009/04/why_eliminate_the_peer-review.php). Therefore, a theoretical source of funding would simply be abolition of submitting unfunded grant applications. However, if it was known which grants would be funded, the review process would be unnecessary.

I am not proposing that NIH fund MBRF, at least not now. If I were, this proposal would be no different from the multiple, existing cries for more money dedicated to research. While I support that, the essence of this proposal is different. Simply taking money from NIH would require that that money not be spent elsewhere in NIH.

Institutions

Some institutions provide “bridge” or interim funding http://www.bumc.bu.edu/medicine/research-in-the-department/announcement-of-bridge-funding-application-deadlines/ .However, such mechanisms are not universal. If such a policy became universal and easy to access, my goal would be accomplished.

Other fund-raising options—researcher initiated.

Here are a few other ideas: MBRF could be a required use of overhead funds. Royalties from research inventions that currently go to institutions could be used. Science-related art and music is another potential source of income.

HOW TO CHOOSE WHO GETS AWARDS?

Ideally, if a person contributes, that person should automatically get an award when you needed. However, initially, the fund will not be large enough do this.

Criteria for receiving awards will be set by the Board of Directors. A formula would be developed. It could reflect: order in which application was received, length of time without funding will be derived. Critical to the MBRF plan is that it would NOT be based on peer-review.

OBJECTIONS

This proposal will not solve all problems in American academic basic biomedical research. However, it is a modest proposal as a start to improving American science. Objections will certainly arise to this proposal, particularly about its practicality. This has been addressed throughout the proposal. (1) Another objection is the lack of peer-review. (2) Another objection is that this may be abused. (3) Finally, it may be objected that this money is TOO low: it is not enough to perform research.

(1) Undermines peer-review system

Although criticism has been raised against it (http://en.wikipedia.org/wiki/Peer_review), peer-review has proven to be a “best practice” for allocating funds. Its purpose is to identify work most deserving of funding. I do not object to peer-review; in fact, I support it. Ideally, applications are judged and funded purely on the basis of merit, in contrast to arbitrary or capricious ways. Traditional ways may be to fund one’s friends and deny funding to one’s enemies. Peer-review is certainly preferable to graft or kickback payments.

The current proposal is for a “tweaking,” a refinement of the process. It is intended for cases in which the peer-review process does not succeed in achieving the goal for which is it intended.

(2) Abuse: INCENTIVES TO AVOID ABUSE

First, this level of funding is very low, making the incentive to cheat very low. Moreover, many people who do not succeed at the NIH level, are able to procure funding from other sources. This is for people who do not succeed, even from other sources. However, I believe that the requirement to contribute may eliminate “free-loaders.”

(3) Award not high enough

The low level of funding may be considered a reason NOT to do this. It may be felt that the amount is too low to permit productivity. I have heard this raised, primarily by highly successful fund-raisers. Such individuals may be unfamiliar with the situation being discussed here.

Clearly the amount of funding must be evaluated regularly. Also, it will depend on the specifics of each researcher’s field.

Keeping the monetary level low is a strength of this proposal. First, this is meant for minimal survival. If this funding was at a higher level, it would not be the minimum required for sustainability. Moreover, higher level would not be feasible—it would take on the aspects of big money funding of science.

Conclusion

This document does not have all the answers. My purpose here is to publicize the basic concept of MBRF and that it could, at least in part, be initiated and funded by researchers. In addition, I propose a number of possible routes to achieving MBRF.

Advocacy groups for science funding:

http://www.aboutastra.org/about/index.asp

http://www.cnsfweb.org/